Multiple signalling pathways, including PI3K/AKT, RAF/MEK/ERK, STAT3, and NF‐κB, are constitutively activated in CLL cells.14, 15, 16, 17, 18, 19 Given the pivotal role of PI3K/AKT in cancer initiation, growth, proliferation, and survival, an increasing number of small molecular inhibitors that target this pathway have been developed. This evidence concerns the gene AKT1 and B-cell chronic lymphocytic leukemia.